Dear Editor,
We have read the research article "The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial" by Seyyedebrahimi et al., the authors presented comparative study results of resveratrol on oxidative stress parameters in type 2 diabetes mellitus (T2DM) participants [1] . We would like to request the authors to clarify or elucidate the following points for further understanding.
First, the authors mentioned that participants were randomized using a stratification method in a double-blind manner and did not mention about the criteria for the same [1] . However, stratification method can be performed based on different factors, i.e., gender, age or other demographic characteristics and leads to bias in grouping [2] .
Second, the authors mentioned that patients were refrained from the anti-inflammatory supplementation during the entire study. However, the patients were on statins in both the groups, i.e., 75% in placebo and 70% in resveratrol and these itself have an anti-inflammatory effect [3] .
Third, in Fig. 1 , the number of participants in the placebo group was presented as 25, but, in Table 1 it is mentioned as 18.
Fourth, a dose of resveratrol was considered as 800 mg/ day, but, did not mention the reference for this dose as 800 mg/day seems to be high.
Fifth, the baseline HOMA-IR value of placebo mentioned as 5.75 ± 5.74, which means the mean and the standard deviation in this group are same, i.e., 11.49 or 0.01. Thus, there is a large variation in this group.
We would be highly obliged for your kind consideration of the above-mentioned clarifications in your article to understand more beneficial effects of bioactive compound i.e., resveratrol on oxidative parameters in T2DM.
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